Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.

about

Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.

Item

http://www.wikidata.org/entity/Q50108062

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@en

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@nl

type

Item

label

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@en

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@nl

prefLabel

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@en

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@nl

P1476

Biosimilars in rheumatology: r ...... e in Middle Eastern countries.

@en

P2093

Bassel El Zorkany

http://www.w3.org/2001/XMLSchema#string

Hani Al Moallim

http://www.w3.org/2001/XMLSchema#string

Imad Uthman

http://www.w3.org/2001/XMLSchema#string

Jamal Al Saleh

http://www.w3.org/2001/XMLSchema#string

Mohamed Mounir

http://www.w3.org/2001/XMLSchema#string

Nizar Al Ani

http://www.w3.org/2001/XMLSchema#string

Samar Al Emadi

http://www.w3.org/2001/XMLSchema#string

Yasser El Dershaby

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology

The changing landscape of biosimilars in rheumatology

Clinical trial development for biosimilars

Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

Rheumatoid arthritis in Saudi Arabia.

A practical guide about biosimilar data for health care providers treating inflammatory diseases

P304

1143-1152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S10067-018-3982-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29411181

http://www.w3.org/2001/XMLSchema#string

P932

5913383

http://www.w3.org/2001/XMLSchema#string